Modeling Huntington's disease with induced pluripotent stem cells

Molecular and Cellular Neuroscience

Volumn 56, Issue , 2013, Pages 50-64

  Kaye, Julia A ^a   Finkbeiner, Steven ^a,b,c,d,e  

^a GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Taube Koret Center for Neurodegenerative Disease Research   (United States)

^e Hellman Family Foundation Program in Alzheimer's Disease Research   (United States)

Author keywords

Huntington's disease; Induced pluripotent stem cells; IPSC; MSN; Neurodegenerative disease; Stem cell models

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; FIBROBLAST GROWTH FACTOR; SONIC HEDGEHOG PROTEIN; WNT PROTEIN;

BRAIN DEVELOPMENT; CELL DIFFERENTIATION; DRUG SCREENING; EMBRYONIC STEM CELL; FIBROBLAST; GENE EXPRESSION; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; MEDIUM SPINY NEURON; NERVE CELL; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION;

HUNTINGTON'S DISEASE; INDUCED PLURIPOTENT STEM CELLS; IPSC; MSN; NEURODEGENERATIVE DISEASE; STEM CELL MODELS;

ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; EMBRYONIC STEM CELLS; HUMANS; HUNTINGTON DISEASE; INDUCED PLURIPOTENT STEM CELLS; MICE; NEUROGENESIS; NEURONS;

MURINAE;

EID: 84876313188     PISSN: 10447431     EISSN: 10959327     Source Type: Journal    
DOI: 10.1016/j.mcn.2013.02.005     Document Type: Review

References (208)

1. Abranches E., Silva M., Pradier L., Schulz H., Hummel O., Henrique D., Bekman E. Neural differentiation of embryonic stem cells in vitro: a road map to neurogenesis in the embryo. PLoS One 2009, 4:e6286.
2. Albin R.L., Reiner A., Anderson K.D., Dure L.S., Handelin B., Balfour R., Whetsell W.O., Penney J.B., Young A.B. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann. Neurol. 1992, 31:425-430.
3. Allman J.M., Tetreault N.A., Hakeem A.Y., Park S. The von Economo neurons in apes and humans. Am. J. Hum. Biol. 2011, 23:5-21.
4. An M.C., Zhang N., Scott G., Montoro D., Wittkop T., Mooney S., Melov S., Ellerby L.M. Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 2012, 11(2):253-263. (Aug. 3).
5. Andrew S.E., Goldberg Y.P., Kremer B., Telenius H., Theilmann J., Adam S., Starr E., Squitieri F., Lin B., Kalchman M.A., et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat. Genet. 1993, 4:398-403.
6. Arlotta P., Molyneaux B.J., Jabaudon D., Yoshida Y., Macklis J.D. Ctip2 controls the differentiation of medium spiny neurons and the establishment of the cellular architecture of the striatum. J. Neurosci. 2008, 28:622-632.
7. Arnulf I., Nielsen J., Lohmann E., Schiefer J., Wild E., Jennum P., Konofal E., Walker M., Oudiette D., Tabrizi S., Durr A. Rapid eye movement sleep disturbances in Huntington disease. Arch. Neurol. 2008, 65:482-488.
8. Arrasate M., Finkbeiner S. Protein aggregates in Huntington's disease. Exp. Neurol. 2012, 238:1-11.
9. Arrasate M., Mitra S., Schweitzer E.S., Segal M.R., Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004, 431:805-810.
10. Aubry L., Bugi A., Lefort N., Rousseau F., Peschanski M., Perrier A.L. Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:16707-16712.
11. Augood S.J., Faull R.L., Emson P.C. Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann. Neurol. 1997, 42:215-221.
12. Bachoud-Levi A.C., Remy P., Nguyen J.P., Brugieres P., Lefaucheur J.P., Bourdet C., Baudic S., Gaura V., Maison P., Haddad B., Boisse M.F., Grandmougin T., Jeny R., Bartolomeo P., Dalla Barba G., Degos J.D., Lisovoski F., Ergis A.M., Pailhous E., Cesaro P., Hantraye P., Peschanski M. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 2000, 356:1975-1979.
13. Bachoud-Levi A.C., Gaura V., Brugieres P., Lefaucheur J.P., Boisse M.F., Maison P., Baudic S., Ribeiro M.J., Bourdet C., Remy P., Cesaro P., Hantraye P., Peschanski M. Effect of fetal neural transplants in patients with Huntington's disease 6years after surgery: a long-term follow-up study. Lancet Neurol. 2006, 5:303-309.
14. Backman M., Machon O., Mygland L., van den Bout C.J., Zhong W., Taketo M.M., Krauss S. Effects of canonical Wnt signaling on dorso-ventral specification of the mouse telencephalon. Dev. Biol. 2005, 279:155-168.
15. Bain G., Kitchens D., Yao M., Huettner J.E., Gottlieb D.I. Embryonic stem cells express neuronal properties in vitro. Dev. Biol. 1995, 168:342-357.
16. Baldo B., Weiss A., Parker C.N., Bibel M., Paganetti P., Kaupmann K. A screen for enhancers of clearance identifies huntingtin as a heat shock protein 90 (Hsp90) client protein. J. Biol. Chem. 2012, 287:1406-1414.
17. Bano D., Zanetti F., Mende Y., Nicotera P. Neurodegenerative processes in Huntington's disease. Cell Death Dis. 2011, 2:e228.
18. Basser P.J., Pierpaoli C. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J. Magn. Reson. B 1996, 111:209-219.
19. Batista C.M., Kippin T.E., Willaime-Morawek S., Shimabukuro M.K., Akamatsu W., van der Kooy D. A progressive and cell non-autonomous increase in striatal neural stem cells in the Huntington's disease R6/2 mouse. J. Neurosci. 2006, 26:10452-10460.
20. Baydyuk M., Russell T., Liao G.Y., Zang K., An J.J., Reichardt L.F., Xu B. TrkB receptor controls striatal formation by regulating the number of newborn striatal neurons. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:1669-1674.
21. Ben-David U., Kopper O., Benvenisty N. Expanding the boundaries of embryonic stem cells. Cell Stem Cell 2012, 10:666-677.
22. Benraiss A., Chmielnicki E., Lerner K., Roh D., Goldman S.A. Adenoviral brain-derived neurotrophic factor induces both neostriatal and olfactory neuronal recruitment from endogenous progenitor cells in the adult forebrain. J. Neurosci. 2001, 21:6718-6731.
23. Bibb J.A., Yan Z., Svenningsson P., Snyder G.L., Pieribone V.A., Horiuchi A., Nairn A.C., Messer A., Greengard P. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:6809-6814.
24. Bilican B., Serio A., Barmada S.J., Nishimura A.L., Sullivan G.J., Carrasco M., Phatnani H.P., Puddifoot C.A., Story D., Fletcher J., Park I.H., Friedman B.A., Daley G.Q., Wyllie D.J., Hardingham G.E., Wilmut I., Finkbeiner S., Maniatis T., Shaw C.E., Chandran S. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(15):5803-5808. (Apr. 10).
25. Blockx I., De Groof G., Verhoye M., Van Audekerke J., Raber K., Poot D., Sijbers J., Osmand A.P., Von Horsten S., Van der Linden A. Microstructural changes observed with DKI in a transgenic Huntington rat model: evidence for abnormal neurodevelopment. Neuroimage 2012, 59:957-967.
26. Blum D., Hourez R., Galas M.C., Popoli P., Schiffmann S.N. Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics. Lancet Neurol. 2003, 2:366-374.
27. Borovecki F., Lovrecic L., Zhou J., Jeong H., Then F., Rosas H.D., Hersch S.M., Hogarth P., Bouzou B., Jensen R.V., Krainc D. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11023-11028.
28. Bradford J., Shin J.Y., Roberts M., Wang C.E., Sheng G., Li S., Li X.J. Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. J. Biol. Chem. 2010, 285:10653-10661.
29. Bradley C.K., Scott H.A., Chami O., Peura T.T., Dumevska B., Schmidt U., Stojanov T. Derivation of Huntington's disease-affected human embryonic stem cell lines. Stem Cells Dev. 2011, 20:495-502.
30. Brennand K.J., Simone A., Jou J., Gelboin-Burkhart C., Tran N., Sangar S., Li Y., Mu Y., Chen G., Yu D., McCarthy S., Sebat J., Gage F.H. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011, 473:221-225.
31. Camnasio S., Carri A.D., Lombardo A., Grad I., Mariotti C., Castucci A., Rozell B., Riso P.L., Castiglioni V., Zuccato C., Rochon C., Takashima Y., Diaferia G., Biunno I., Gellera C., Jaconi M., Smith A., Hovatta O., Naldini L., Di Donato S., Feki A., Cattaneo E. The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity. Neurobiol. Dis. 2012, 46:41-51.
32. Carri A.D., Onorati M., Lelos M.J., Castiglioni V., Faedo A., Menon R., Camnasio S., Vuono R., Spaiardi P., Talpo F., Toselli M., Martino G., Barker R.A., Dunnett S.B., Biella G., Cattaneo E. Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-32+ medium-sized spiny neurons. Development 2013, 140:301-312.
33. Castiglioni V., Onorati M., Rochon C., Cattaneo E. Induced pluripotent stem cell lines from Huntington's disease mice undergo neuronal differentiation while showing alterations in the lysosomal pathway. Neurobiol. Dis. 2011, 46(1):30-40. (Apr.).
34. Cattaneo E., Zuccato C., Tartari M. Normal huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci. 2005, 6:919-930.
35. Cha J.H. Transcriptional signatures in Huntington's disease. Prog. Neurobiol. 2007, 83:228-248.
36. Chae J.I., Kim D.W., Lee N., Jeon Y.J., Jeon I., Kwon J., Kim J., Soh Y., Lee D.S., Seo K.S., Choi N.J., Park B.C., Kang S.H., Ryu J., Oh S.H., Shin D.A., Lee D.R., Do J.T., Park I.H., Daley G.Q., Song J. Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient. Biochem. J. 2012, 446:359-371.
37. Chan A.W., Cheng P.H., Neumann A., Yang J.J. Reprogramming Huntington monkey skin cells into pluripotent stem cells. Cell. Reprogram. 2010, 12:509-517.
38. Chatzi C., Brade T., Duester G. Retinoic acid functions as a key GABAergic differentiation signal in the basal ganglia. PLoS Biol. 2011, 9:e1000609.
39. Chiang M.C., Lee Y.C., Huang C.L., Chern Y. cAMP-response element-binding protein contributes to suppression of the A2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues. J. Biol. Chem. 2005, 280:14331-14340.
40. Ciarmiello A., Cannella M., Lastoria S., Simonelli M., Frati L., Rubinsztein D.C., Squitieri F. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J. Nucl. Med. 2006, 47:215-222.
41. Ciccolini F., Svendsen C.N. Neurotrophin responsiveness is differentially regulated in neurons and precursors isolated from the developing striatum. J. Mol. Neurosci. 2001, 17:25-33.
42. Clowry G., Molnar Z., Rakic P. Renewed focus on the developing human neocortex. J. Anat. 2010, 217:276-288.
43. Conforti P., Camnasio S., Mutti C., Valenza M., Thompson M., Fossale E., Zeitlin S., Macdonald M.E., Zuccato C., Cattaneo E. Lack of huntingtin promotes neural stem cells differentiation into glial cells while neurons expressing huntingtin with expanded polyglutamine tracts undergo cell death. Neurobiol. Dis. 2013, 50:160-170.
44. Curtis M.A., Penney E.B., Pearson A.G., van Roon-Mom W.M., Butterworth N.J., Dragunow M., Connor B., Faull R.L. Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:9023-9027.
45. Curtis M.A., Penney E.B., Pearson J., Dragunow M., Connor B., Faull R.L. The distribution of progenitor cells in the subependymal layer of the lateral ventricle in the normal and Huntington's disease human brain. Neuroscience 2005, 132:777-788.
46. Czepiel M., Balasubramaniyan V., Schaafsma W., Stancic M., Mikkers H., Huisman C., Boddeke E., Copray S. Differentiation of induced pluripotent stem cells into functional oligodendrocytes. Glia 2011, 59:882-892.
47. Danjo T., Eiraku M., Muguruma K., Watanabe K., Kawada M., Yanagawa Y., Rubenstein J.L., Sasai Y. Subregional specification of embryonic stem cell-derived ventral telencephalic tissues by timed and combinatory treatment with extrinsic signals. J. Neurosci. 2011, 31:1919-1933.
48. Desplats P.A., Lambert J.R., Thomas E.A. Functional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington's disease. Neurobiol. Dis. 2008, 31:298-308.
49. Dey N.D., Bombard M.C., Roland B.P., Davidson S., Lu M., Rossignol J., Sandstrom M.I., Skeel R.L., Lescaudron L., Dunbar G.L. Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington's disease. Behav. Brain Res. 2010, 214:193-200.
50. DiFiglia M., Sapp E., Chase K., Schwarz C., Meloni A., Young C., Martin E., Vonsattel J.P., Carraway R., Reeves S.A. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 1995, 14:1075-1081.
51. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
52. DiProspero N.A., Chen E.Y., Charles V., Plomann M., Kordower J.H., Tagle D.A. Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J. Neurocytol. 2004, 33:517-533.
53. Dolmetsch R., Geschwind D.H. The human brain in a dish: the promise of iPSC-derived neurons. Cell 2011, 145:831-834.
54. Duff K., Paulsen J.S., Beglinger L.J., Langbehn D.R., Stout J.C. Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol. Psychiatry 2007, 62:1341-1346.
55. Dunnett S.B., Rosser A.E. Stem cell transplantation for Huntington's disease. Exp. Neurol. 2007, 203:279-292.
56. Duyao M.P., Auerbach A.B., Ryan A., Persichetti F., Barnes G.T., McNeil S.M., Ge P., Vonsattel J.P., Gusella J.F., Joyner A.L., et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 1995, 269:407-410.
57. Ebert A.D., Yu J., Rose F.F., Mattis V.B., Lorson C.L., Thomson J.A., Svendsen C.N. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009, 457:277-280.
58. Ebert A.D., Barber A.E., Heins B.M., Svendsen C.N. Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease. Exp. Neurol. 2010, 224:155-162.
59. Egawa N., Kitaoka S., Tsukita K., Naitoh M., Takahashi K., Yamamoto T., Adachi F., Kondo T., Okita K., Asaka I., Aoi T., Watanabe A., Yamada Y., Morizane A., Takahashi J., Ayaki T., Ito H., Yoshikawa K., Yamawaki S., Suzuki S., Watanabe D., Hioki H., Kaneko T., Makioka K., Okamoto K., Takuma H., Tamaoka A., Hasegawa K., Nonaka T., Hasegawa M., Kawata A., Yoshida M., Nakahata T., Takahashi R., Marchetto M.C., Gage F.H., Yamanaka S., Inoue H. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci. Transl. Med. 2012, 4:145ra104.
60. Eiraku M., Sasai Y. Mouse embryonic stem cell culture for generation of three-dimensional retinal and cortical tissues. Nat. Protoc. 2012, 7:69-79.
61. Eiraku M., Watanabe K., Matsuo-Takasaki M., Kawada M., Yonemura S., Matsumura M., Wataya T., Nishiyama A., Muguruma K., Sasai Y. Self-organized formation of polarized cortical tissues from ESCs and its active manipulation by extrinsic signals. Cell Stem Cell 2008, 3:519-532.
62. El-Akabawy G., Medina L.M., Jeffries A., Price J., Modo M. Purmorphamine increases DARPP-32 differentiation in human striatal neural stem cells through the Hedgehog pathway. Stem Cells Dev. 2011, 20:1873-1887.
63. Evans A.E., Kelly C.M., Precious S.V., Rosser A.E. Molecular regulation of striatal development: a review. Anat. Res. Int. 2012, 2012:106529.
64. Fentress J.C., Stanfield B.B., Cowan W.M. Observation on the development of the striatum in mice and rats. Anat. Embryol. 1981, 163:275-298.
65. Ferrante R.J., Kowall N.W., Richardson E.P. Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J. Neurosci. 1991, 11:3877-3887.
66. Ferrer-Costa C., Orozco M., de la Cruz X. Characterization of disease-associated single amino acid polymorphisms in terms of sequence and structure properties. J. Mol. Biol. 2002, 315:771-786.
67. Finkbeiner S. Huntington's disease. Cold Spring Harb. Perspect. Biol. 2011, 3.
68. Gaspard N., Bouschet T., Hourez R., Dimidschstein J., Naeije G., van den Ameele J., Espuny-Camacho I., Herpoel A., Passante L., Schiffmann S.N., Gaillard A., Vanderhaeghen P. An intrinsic mechanism of corticogenesis from embryonic stem cells. Nature 2008, 455:351-357.
69. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization. J. Neural Transm. Suppl. 1992, 36:43-59.
70. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Annu. Rev. Neurosci. 1992, 15:285-320.
71. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma F.J., Sibley D.R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990, 250:1429-1432.
72. Gharib W.H., Robinson-Rechavi M. When orthologs diverge between human and mouse. Brief. Bioinform. 2011, 12:436-441.
73. Giedd J.N. Structural magnetic resonance imaging of the adolescent brain. Ann. N. Y. Acad. Sci. 2004, 1021:77-85.
74. Gil J.M., Mohapel P., Araujo I.M., Popovic N., Li J.Y., Brundin P., Petersen A. Reduced hippocampal neurogenesis in R6/2 transgenic Huntington's disease mice. Neurobiol. Dis. 2005, 20:744-751.
75. Ginis I., Luo Y., Miura T., Thies S., Brandenberger R., Gerecht-Nir S., Amit M., Hoke A., Carpenter M.K., Itskovitz-Eldor J., Rao M.S. Differences between human and mouse embryonic stem cells. Dev. Biol. 2004, 269:360-380.
76. Godin J.D., Colombo K., Molina-Calavita M., Keryer G., Zala D., Charrin B.C., Dietrich P., Volvert M.L., Guillemot F., Dragatsis I., Bellaiche Y., Saudou F., Nguyen L., Humbert S. Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis. Neuron 2010, 67:392-406.
77. Gourfinkel-An I., Parain K., Hartmann A., Mangiarini L., Brice A., Bates G., Hirsch E.C. Changes in GAD67 mRNA expression evidenced by in situ hybridization in the brain of R6/2 transgenic mice. J. Neurochem. 2003, 86:1369-1378.
78. Gulacsi A.A., Anderson S.A. Beta-catenin-mediated Wnt signaling regulates neurogenesis in the ventral telencephalon. Nat. Neurosci. 2008, 11:1383-1391.
79. Gunhaga L., Marklund M., Sjodal M., Hsieh J.C., Jessell T.M., Edlund T. Specification of dorsal telencephalic character by sequential Wnt and FGF signaling. Nat. Neurosci. 2003, 6:701-707.
80. Gutekunst C.-A., Li S.-H., Yi H., Mulroy J.S., Kuemmerle S., Jones R., Rye D., Ferrante R.J., Hersch S.M., Li X.-J. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci. 1999, 19:2522-2534.
81. Han I., You Y., Kordower J.H., Brady S.T., Morfini G.A. Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features. J. Neurochem. 2010, 113:1073-1091.
82. Heiman M., Schaefer A., Gong S., Peterson J.D., Day M., Ramsey K.E., Suarez-Farinas M., Schwarz C., Stephan D.A., Surmeier D.J., Greengard P., Heintz N. A translational profiling approach for the molecular characterization of CNS cell types. Cell 2008, 135:738-748.
83. Hickey M.A., Chesselet M.F. Apoptosis in Huntington's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:255-265.
84. Hoch R.V., Rubenstein J.L., Pleasure S. Genes and signaling events that establish regional patterning of the mammalian forebrain. Semin. Cell Dev. Biol. 2009, 20:378-386.
85. Hodges A., Strand A.D., Aragaki A.K., Kuhn A., Sengstag T., Hughes G., Elliston L.A., Hartog C., Goldstein D.R., Thu D., Hollingsworth Z.R., Collin F., Synek B., Holmans P.A., Young A.B., Wexler N.S., Delorenzi M., Kooperberg C., Augood S.J., Faull R.L., Olson J.M., Jones L., Luthi-Carter R. Regional and cellular gene expression changes in human Huntington's disease brain. Hum. Mol. Genet. 2006, 15:965-977.
86. Huang E.J., Reichardt L.F. Neurotrophins: roles in neuronal development and function. Annu. Rev. Neurosci. 2001, 24:677-736.
87. Huang Q., Zhou D., Sapp E., Aizawa H., Ge P., Bird E.D., Vonsattel J.P., DiFiglia M. Quinolinic acid-induced increases in calbindin D28k immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington's disease. Neuroscience 1995, 65:397-407.
88. Itskovitz-Eldor J., Schuldiner M., Karsenti D., Eden A., Yanuka O., Amit M., Soreq H., Benvenisty N. Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Mol. Med. 2000, 6:88-95.
89. Jacobsen J.C., Gregory G.C., Woda J.M., Thompson M.N., Coser K.R., Murthy V., Kohane I.S., Gusella J.F., Seong I.S., MacDonald M.E., Shioda T., Lee J.M. HD CAG-correlated gene expression changes support a simple dominant gain of function. Hum. Mol. Genet. 2011, 20:2846-2860.
90. Jain M., Armstrong R.J., Barker R.A., Rosser A.E. Cellular and molecular aspects of striatal development. Brain Res. Bull. 2001, 55:533-540.
91. Jeon I., Lee N., Li J.Y., Park I.H., Park K.S., Moon J., Shim S.H., Choi C., Chang D.J., Kwon J., Oh S.H., Shin D.A., Kim H.S., Do J.T., Lee D.R., Kim M., Kang K.S., Daley G.Q., Brundin P., Song J. Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells. Stem Cells 2012, 30:2054-2062.
92. Joyce N., Annett G., Wirthlin L., Olson S., Bauer G., Nolta J.A. Mesenchymal stem cells for the treatment of neurodegenerative disease. Regen. Med. 2010, 5:933-946.
93. Julien C.L., Thompson J.C., Wild S., Yardumian P., Snowden J.S., Turner G., Craufurd D. Psychiatric disorders in preclinical Huntington's disease. J. Neurol. Neurosurg. Psychiatry 2007, 78:939-943.
94. Juopperi T.A., Kim W.R., Chiang C.H., Yu H., Margolis R.L., Ross C.A., Ming G.L., Song H. Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells. Mol. Brain 2012, 5:17.
95. Kim M., Lee S.T., Chu K., Kim S.U. Stem cell-based cell therapy for Huntington disease: a review. Neuropathology 2008, 28:1-9.
96. Kohtz J.D., Baker D.P., Corte G., Fishell G. Regionalization within the mammalian telencephalon is mediated by changes in responsiveness to Sonic Hedgehog. Development 1998, 125:5079-5089.
97. Kratter I.H., Finkbeiner S. PolyQ disease: too many Qs, too much function?. Neuron 2010, 67:897-899.
98. Krencik R., Weick J.P., Liu Y., Zhang Z.J., Zhang S.C. Specification of transplantable astroglial subtypes from human pluripotent stem cells. Nat. Biotechnol. 2011, 29:528-534.
99. Kulbatski I. Stem/precursor cell-based CNS therapy: the importance of circumventing immune suppression by transplanting autologous cells. Stem Cell Rev. 2010, 6:405-410.
100. Laeng P., Pitts R.L., Lemire A.L., Drabik C.E., Weiner A., Tang H., Thyagarajan R., Mallon B.S., Altar C.A. The mood stabilizer valproic acid stimulates GABA neurogenesis from rat forebrain stem cells. J. Neurochem. 2004, 91:238-251.
101. Langbehn D.R., Brinkman R.R., Falush D., Paulsen J.S., Hayden M.R. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin. Genet. 2004, 65:267-277.
102. Lazic S.E., Grote H., Armstrong R.J., Blakemore C., Hannan A.J., van Dellen A., Barker R.A. Decreased hippocampal cell proliferation in R6/1 Huntington's mice. Neuroreport 2004, 15:811-813.
103. Lazic S.E., Goodman A.O., Grote H.E., Blakemore C., Morton A.J., Hannan A.J., van Dellen A., Barker R.A. Olfactory abnormalities in Huntington's disease: decreased plasticity in the primary olfactory cortex of R6/1 transgenic mice and reduced olfactory discrimination in patients. Brain Res. 2007, 1151:219-226.
104. Lee G., Papapetrou E.P., Kim H., Chambers S.M., Tomishima M.J., Fasano C.A., Ganat Y.M., Menon J., Shimizu F., Viale A., Tabar V., Sadelain M., Studer L. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 2009, 461:402-406.
105. Lee J.K., Mathews K., Schlaggar B., Perlmutter J., Paulsen J.S., Epping E., Burmeister L., Nopoulos P. Measures of growth in children at risk for Huntington disease. Neurology 2012, 79(7):668-674. (Aug. 14).
106. Li S.H., Li X.J. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet. 2004, 20:146-154.
107. Li X.J., Zhang X., Johnson M.A., Wang Z.B., Lavaute T., Zhang S.C. Coordination of sonic hedgehog and Wnt signaling determines ventral and dorsal telencephalic neuron types from human embryonic stem cells. Development 2009, 136:4055-4063.
108. Liu F.C., Graybiel A.M. Transient calbindin-D28k-positive systems in the telencephalon: ganglionic eminence, developing striatum and cerebral cortex. J. Neurosci. 1992, 12:674-690.
109. Lobo M.K., Karsten S.L., Gray M., Geschwind D.H., Yang X.W. FACS-array profiling of striatal projection neuron subtypes in juvenile and adult mouse brains. Nat. Neurosci. 2006, 9:443-452.
110. Lobo M.K., Cui Y., Ostlund S.B., Balleine B.W., Yang X.W. Genetic control of instrumental conditioning by striatopallidal neuron-specific S1P receptor Gpr6. Nat. Neurosci. 2007, 10:1395-1397.
111. Logan C.Y., Nusse R. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 2004, 20:781-810.
112. Long J.D., Matson W.R., Juhl A.R., Leavitt B.R., Paulsen J.S. 8OHdG as a marker for Huntington disease progression. Neurobiol. Dis. 2012, 46:625-634.
113. Lorincz M.T., Zawistowski V.A. Expanded CAG repeats in the murine Huntington's disease gene increases neuronal differentiation of embryonic and neural stem cells. Mol. Cell. Neurosci. 2009, 40:1-13.
114. Lovrecic L., Kastrin A., Kobal J., Pirtosek Z., Krainc D., Peterlin B. Gene expression changes in blood as a putative biomarker for Huntington's disease. Mov. Disord. 2009, 24:2277-2281.
115. Low V.F., Dragunow M., Tippett L.J., Faull R.L., Curtis M.A. No change in progenitor cell proliferation in the hippocampus in Huntington's disease. Neuroscience 2011, 199:577-588.
116. Luthi-Carter R., Strand A., Peters N.L., Solano S.M., Hollingsworth Z.R., Menon A.S., Frey A.S., Spektor B.S., Penney E.B., Schilling G., Ross C.A., Borchelt D.R., Tapscott S.J., Young A.B., Cha J.H., Olson J.M. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 2000, 9:1259-1271.
117. Ma L., Hu B., Liu Y., Vermilyea S.C., Liu H., Gao L., Sun Y., Zhang X., Zhang S.C. Human embryonic stem cell-derived GABA neurons correct locomotion deficits in quinolinic acid-lesioned mice. Cell Stem Cell 2012, 10(4):455-464. (Apr. 6).
118. Mahley R.W., Weisgraber K.H., Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:5644-5651.
119. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
120. Marchetto M.C., Carromeu C., Acab A., Yu D., Yeo G.W., Mu Y., Chen G., Gage F.H., Muotri A.R. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2010, 143:527-539.
121. Marin O., Rubenstein J.L. A long, remarkable journey: tangential migration in the telencephalon. Nat. Rev. Neurosci. 2001, 2:780-790.
122. Mason I. Initiation to end point: the multiple roles of fibroblast growth factors in neural development. Nat. Rev. Neurosci. 2007, 8:583-596.
123. Mateizel I., De Temmerman N., Ullmann U., Cauffman G., Sermon K., Van de Velde H., De Rycke M., Degreef E., Devroey P., Liebaers I., Van Steirteghem A. Derivation of human embryonic stem cell lines from embryos obtained after IVF and after PGD for monogenic disorders. Hum. Reprod. 2006, 21:503-511.
124. Meador-Woodruff J.H., Damask S.P., Wang J., Haroutunian V., Davis K.L., Watson S.J. Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology 1996, 15:17-29.
125. Menalled L., Zanjani H., MacKenzie L., Koppel A., Carpenter E., Zeitlin S., Chesselet M.F. Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease. Exp. Neurol. 2000, 162:328-342.
126. Mercugliano M., Soghomonian J.J., Qin Y., Nguyen H.Q., Feldblum S., Erlander M.G., Tobin A.J., Chesselet M.F. Comparative distribution of messenger RNAs encoding glutamic acid decarboxylases (Mr 65,000 and Mr 67,000) in the basal ganglia of the rat. J. Comp. Neurol. 1992, 318:245-254.
127. Mestas J., Hughes C.C. Of mice and not men: differences between mouse and human immunology. J. Immunol. 2004, 172:2731-2738.
128. Mestre T., Ferreira J., Coelho M.M., Rosa M., Sampaio C. Therapeutic interventions for disease progression in Huntington's disease. Cochrane Database Syst. Rev. 2009, CD006455.
129. Miller J., Arrasate M., Shaby B.A., Mitra S., Masliah E., Finkbeiner S. Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into Huntington's disease molecular pathogenesis. J. Neurosci. 2010, 30:10541-10550.
130. Mizushima K., Miyamoto Y., Tsukahara F., Hirai M., Sakaki Y., Ito T. A novel G-protein-coupled receptor gene expressed in striatum. Genomics 2000, 69:314-321.
131. Mochel F., Durant B., Meng X., O'Callaghan J., Yu H., Brouillet E., Wheeler V.C., Humbert S., Schiffmann R., Durr A. Early alterations of brain cellular energy homeostasis in Huntington disease models. J. Biol. Chem. 2012, 287:1361-1370.
132. Molero A.E., Gokhan S., Gonzalez S., Feig J.L., Alexandre L.C., Mehler M.F. Impairment of developmental stem cell-mediated striatal neurogenesis and pluripotency genes in a knock-in model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:21900-21905.
133. Nei M., Xu P., Glazko G. Estimation of divergence times from multiprotein sequences for a few mammalian species and several distantly related organisms. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:2497-2502.
134. Niclis J.C., Trounson A.O., Dottori M., Ellisdon A.M., Bottomley S.P., Verlinsky Y., Cram D.S. Human embryonic stem cell models of Huntington disease. Reprod. Biomed. Online 2009, 19:106-113.
135. Nimchinsky E.A., Gilissen E., Allman J.M., Perl D.P., Erwin J.M., Hof P.R. A neuronal morphologic type unique to humans and great apes. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:5268-5273.
136. Nopoulos P.C., Aylward E.H., Ross C.A., Mills J.A., Langbehn D.R., Johnson H.J., Magnotta V.A., Pierson R.K., Beglinger L.J., Nance M.A., Barker R.A., Paulsen J.S. Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. Brain 2011, 134:137-142.
137. Nordin S., Paulsen J.S., Murphy C. Sensory- and memory-mediated olfactory dysfunction in Huntington's disease. J. Int. Neuropsychol. Soc. 1995, 1:281-290.
138. Oberheim N.A., Wang X., Goldman S., Nedergaard M. Astrocytic complexity distinguishes the human brain. Trends Neurosci. 2006, 29:547-553.
139. Odom D.T., Dowell R.D., Jacobsen E.S., Gordon W., Danford T.W., MacIsaac K.D., Rolfe P.A., Conboy C.M., Gifford D.K., Fraenkel E. Tissue-specific transcriptional regulation has diverged significantly between human and mouse. Nat. Genet. 2007, 39:730-732.
140. Okabe S., Forsberg-Nilsson K., Spiro A.C., Segal M., McKay R.D. Development of neuronal precursor cells and functional postmitotic neurons from embryonic stem cells in vitro. Mech. Dev. 1996, 59:89-102.
141. Olson S.D., Kambal A., Pollock K., Mitchell G.M., Stewart H., Kalomoiris S., Cary W., Nacey C., Pepper K., Nolta J.A. Examination of mesenchymal stem cell-mediated RNAi transfer to Huntington's disease affected neuronal cells for reduction of huntingtin. Mol. Cell. Neurosci. 2012, 49:271-281.
142. Olsson M., Bjorklund A., Campbell K. Early specification of striatal projection neurons and interneuronal subtypes in the lateral and medial ganglionic eminence. Neuroscience 1998, 84:867-876.
143. Ouimet C.C., Miller P.E., Hemmings H.C., Walaas S.I., Greengard P. DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization. J. Neurosci. 1984, 4:111-124.
144. Ouimet C.C., Langley-Gullion K.C., Greengard P. Quantitative immunocytochemistry of DARPP-32-expressing neurons in the rat caudatoputamen. Brain Res. 1998, 808:8-12.
145. Packard M.G., Knowlton B.J. Learning and memory functions of the basal ganglia. Annu. Rev. Neurosci. 2002, 25:563-593.
146. Paek H., Gutin G., Hebert J.M. FGF signaling is strictly required to maintain early telencephalic precursor cell survival. Development 2009, 136:2457-2465.
147. Pankratz M.T., Zhang S.-C. Embryoid bodies and neuroepithelial development. Human Stem Cell Manual. A Laboratory Guide 2007, 185-198. Elsevier, New York. J.F. Loring, R.L. Wesselschmidt, P.H. Schwartz (Eds.).
148. Park I.H., Arora N., Huo H., Maherali N., Ahfeldt T., Shimamura A., Lensch M.W., Cowan C., Hochedlinger K., Daley G.Q. Disease-specific induced pluripotent stem cells. Cell 2008, 134:877-886.
149. Park I.H., Lerou P.H., Zhao R., Huo H., Daley G.Q. Generation of human-induced pluripotent stem cells. Nat. Protoc. 2008, 3:1180-1186.
150. Phillips W., Morton A.J., Barker R.A. Abnormalities of neurogenesis in the R6/2 mouse model of Huntington's disease are attributable to the in vivo microenvironment. J. Neurosci. 2005, 25:11564-11576.
151. Phillips W., Morton A.J., Barker R.A. Limbic neurogenesis/plasticity in the R6/2 mouse model of Huntington's disease. Neuroreport 2006, 17:1623-1627.
152. Pickel V.M., Heras A. Ultrastructural localization of calbindin-D28k and GABA in the matrix compartment of the rat caudate-putamen nuclei. Neuroscience 1996, 71:167-178.
153. Pickel V.M., Sumal K.K., Reis D.J., Miller R.J., Hervonen A. Immunocytochemical localization of enkephalin and substance P in the dorsal tegmental nuclei in human fetal brain. J. Comp. Neurol. 1980, 193:805-814.
154. Rajput P.S., Kharmate G., Somvanshi R.K., Kumar U. Colocalization of dopamine receptor subtypes with dopamine and cAMP-regulated phosphoprotein (DARPP-32) in rat brain. Neurosci. Res. 2009, 65:53-63.
155. Rallu M., Machold R., Gaiano N., Corbin J.G., McMahon A.P., Fishell G. Dorsoventral patterning is established in the telencephalon of mutants lacking both Gli3 and Hedgehog signaling. Development 2002, 129:4963-4974.
156. Rauskolb S., Zagrebelsky M., Dreznjak A., Deogracias R., Matsumoto T., Wiese S., Erne B., Sendtner M., Schaeren-Wiemers N., Korte M., Barde Y.A. Global deprivation of brain-derived neurotrophic factor in the CNS reveals an area-specific requirement for dendritic growth. J. Neurosci. 2010, 30:1739-1749.
157. Reiner A., Del Mar N., Meade C.A., Yang H., Dragatsis I., Zeitlin S., Goldowitz D. Neurons lacking huntingtin differentially colonize brain and survive in chimeric mice. J. Neurosci. 2001, 21:7608-7619.
158. Ross A.L., Leder D.E., Weiss J., Izakovic J., Grichnik J.M. Genomic instability in cultured stem cells: associated risks and underlying mechanisms. Regen. Med. 2011, 6:653-662.
159. Rubenstein J.L., Shimamura K., Martinez S., Puelles L. Regionalization of the prosencephalic neural plate. Annu. Rev. Neurosci. 1998, 21:445-477.
160. Rushton J.P., Ankney C.D. Brain size matters: a reply to Peters. Can. J. Exp. Psychol. 1995, 49:562-569. discussion 570-6.
161. Sanalkumar R., Vidyanand S., Lalitha Indulekha C., James J. Neuronal vs. glial fate of embryonic stem cell-derived neural progenitors (ES-NPs) is determined by FGF2/EGF during proliferation. J. Mol. Neurosci. 2010, 42:17-27.
162. Seo H., Sonntag K.C., Isacson O. Generalized brain and skin proteasome inhibition in Huntington's disease. Ann. Neurol. 2004, 56:319-328.
163. Seok J., Warren H.S., Cuenca A.G., Mindrinos M.N., Baker H.V., Xu W., Richards D.R., McDonald-Smith G.P., Gao H., Hennessy L., Finnerty C.C., Lopez C.M., Honari S., Moore E.E., Minei J.P., Cuschieri J., Bankey P.E., Johnson J.L., Sperry J., Nathens A.B., Billiar T.R., West M.A., Jeschke M.G., Klein M.B., Gamelli R.L., Gibran N.S., Brownstein B.H., Miller-Graziano C., Calvano S.E., Mason P.H., Cobb J.P., Rahme L.G., Lowry S.F., Maier R.V., Moldawer L.L., Herndon D.N., Davis R.W., Xiao W., Tompkins R.G. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. U. S. A 2013, 110:3507-3512. Inflammation, Host Response to Injury LSCRP.
164. Seriola A., Spits C., Simard J.P., Hilven P., Haentjens P., Pearson C.E., Sermon K. Huntington's and myotonic dystrophy hESCs: down-regulated trinucleotide repeat instability and mismatch repair machinery expression upon differentiation. Hum. Mol. Genet. 2011, 20:176-185.
165. Shi Y., Kirwan P., Smith J., Robinson H.P., Livesey F.J. Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses. Nat. Neurosci. 2012, 15:477-486.
166. Shin E., Palmer M.J., Li M., Fricker R.A. GABAergic neurons from mouse embryonic stem cells possess functional properties of striatal neurons in vitro, and develop into striatal neurons in vivo in a mouse model of Huntington's disease. Stem Cell Rev. 2011, 8(2):513-531. (2012 Jun.).
167. Shinya M., Koshida S., Sawada A., Kuroiwa A., Takeda H. Fgf signalling through MAPK cascade is required for development of the subpallial telencephalon in zebrafish embryos. Development 2001, 128:4153-4164.
168. Simpson J.M., Gil-Mohapel J., Pouladi M.A., Ghilan M., Xie Y., Hayden M.R., Christie B.R. Altered adult hippocampal neurogenesis in the YAC128 transgenic mouse model of Huntington disease. Neurobiol. Dis. 2011, 41:249-260.
169. Snell R.G., MacMillan J.C., Cheadle J.P., Fenton I., Lazarou L.P., Davies P., MacDonald M.E., Gusella J.F., Harper P.S., Shaw D.J. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat. Genet. 1993, 4:393-397.
170. Snyder B.R., Chiu A.M., Prockop D.J., Chan A.W. Human multipotent stromal cells (MSCs) increase neurogenesis and decrease atrophy of the striatum in a transgenic mouse model for Huntington's disease. PLoS One 2010, 5:e9347.
171. Song J., Lee S.T., Kang W., Park J.E., Chu K., Lee S.E., Hwang T., Chung H., Kim M. Human embryonic stem cell-derived neural precursor transplants attenuate apomorphine-induced rotational behavior in rats with unilateral quinolinic acid lesions. Neurosci. Lett. 2007, 423:58-61.
172. Sousa V.H., Fishell G. Sonic hedgehog functions through dynamic changes in temporal competence in the developing forebrain. Curr. Opin. Genet. Dev. 2010, 20:391-399.
173. Sramka M., Rattaj M., Molina H., Vojtassak J., Belan V., Ruzicky E. Stereotactic technique and pathophysiological mechanisms of neurotransplantation in Huntington's chorea. Stereotact. Funct. Neurosurg. 1992, 58:79-83.
174. Starling A.J., Andre V.M., Cepeda C., de Lima M., Chandler S.H., Levine M.S. Alterations in N-methyl-d-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease. J. Neurosci. Res. 2005, 82:377-386.
175. Sterneckert J., Stehling M., Bernemann C., Arauzo-Bravo M.J., Greber B., Gentile L., Ortmeier C., Sinn M., Wu G., Ruau D., Zenke M., Brintrup R., Klein D.C., Ko K., Scholer H.R. Neural induction intermediates exhibit distinct roles of Fgf signaling. Stem Cells 2010, 28:1772-1781.
176. Strubing C., Ahnert-Hilger G., Shan J., Wiedenmann B., Hescheler J., Wobus A.M. Differentiation of pluripotent embryonic stem cells into the neuronal lineage in vitro gives rise to mature inhibitory and excitatory neurons. Mech. Dev. 1995, 53:275-287.
177. Sugars K.L., Brown R., Cook L.J., Swartz J., Rubinsztein D.C. Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis. J. Biol. Chem. 2004, 279:4988-4999.
178. Sun Z., Wang H.B., Deng Y.P., Lei W.L., Xie J.P., Meade C.A., Del Mar N., Goldowitz D., Reiner A. Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice. Neurobiol. Dis. 2005, 20:907-917.
179. Schwaller B., Meyer M., Schiffmann S. 'New' functions for 'old' proteins: the role of the calcium-binding proteins calbindin D-28k, calretinin and parvalbumin, in cerebellar physiology. Studies with knockout mice. Cerebellum 2002, 1:241-258.
180. Takahashi K., Liu F.C., Hirokawa K., Takahashi H. Expression of Foxp2, a gene involved in speech and language, in the developing and adult striatum. J. Neurosci. Res. 2003, 73:61-72.
181. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
182. Tamura S., Morikawa Y., Iwanishi H., Hisaoka T., Senba E. Foxp1 gene expression in projection neurons of the mouse striatum. Neuroscience 2004, 124:261-267.
183. Tattersfield A.S., Croon R.J., Liu Y.W., Kells A.P., Faull R.L., Connor B. Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease. Neuroscience 2004, 127:319-332.
184. The HD iPSC, C. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 2012, 11:264-278.
185. Thomas E.A. Striatal specificity of gene expression dysregulation in Huntington's disease. J. Neurosci. Res. 2006, 84:1151-1164.
186. Tong Y., Ha T.J., Liu L., Nishimoto A., Reiner A., Goldowitz D. Spatial and temporal requirements for huntingtin (Htt) in neuronal migration and survival during brain development. J. Neurosci. 2011, 31:14794-14799.
187. Urban N., Martin-Ibanez R., Herranz C., Esgleas M., Crespo E., Pardo M., Crespo-Enriquez I., Mendez-Gomez H.R., Waclaw R., Chatzi C., Alvarez S., Alvarez R., Duester G., Campbell K., de Lera A.R., Vicario-Abejon C., Martinez S., Alberch J., Canals J.M. Nolz1 promotes striatal neurogenesis through the regulation of retinoic acid signaling. Neural Dev. 2010, 5:21.
188. Valenza M., Rigamonti D., Goffredo D., Zuccato C., Fenu S., Jamot L., Strand A., Tarditi A., Woodman B., Racchi M., Mariotti C., Di Donato S., Corsini A., Bates G., Pruss R., Olson J.M., Sipione S., Tartari M., Cattaneo E. Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J. Neurosci. 2005, 25:9932-9939.
189. Van Waes V., Tseng K.Y., Steiner H. GPR88 - a putative signaling molecule predominantly expressed in the striatum: cellular localization and developmental regulation. Basal Ganglia 2011, 1:83-89.
190. Vance J.E., Hayashi H. Formation and function of apolipoprotein E-containing lipoproteins in the nervous system. Biochim. Biophys. Acta 2010, 1801:806-818.
191. Vargiu P., Morte B., Manzano J., Perez J., de Abajo R., Gregor Sutcliffe J., Bernal J. Thyroid hormone regulation of rhes, a novel Ras homolog gene expressed in the striatum. Brain Res. Mol. Brain Res. 2001, 94:1-8.
192. Vazey E.M., Chen K., Hughes S.M., Connor B. Transplanted adult neural progenitor cells survive, differentiate and reduce motor function impairment in a rodent model of Huntington's disease. Exp. Neurol. 2006, 199:384-396.
193. Vazey E.M., Dottori M., Jamshidi P., Tomas D., Pera M.F., Horne M., Connor B. Comparison of transplant efficiency between spontaneously derived and noggin-primed human embryonic stem cell neural precursors in the quinolinic acid rat model of Huntington's disease. Cell Transplant. 2010, 19:1055-1062.
194. Verlinsky Y., Strelchenko N., Kukharenko V., Rechitsky S., Verlinsky O., Galat V., Kuliev A. Human embryonic stem cell lines with genetic disorders. Reprod. Biomed. Online 2005, 10:105-110.
195. Vonsattel J.P., DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 1998, 57:369-384.
196. Waclaw R.R., Wang B., Pei Z., Ehrman L.A., Campbell K. Distinct temporal requirements for the homeobox gene Gsx2 in specifying striatal and olfactory bulb neuronal fates. Neuron 2009, 63:451-465.
197. Walker T.L., Turnbull G.W., Mackay E.W., Hannan A.J., Bartlett P.F. The latent stem cell population is retained in the hippocampus of transgenic Huntington's disease mice but not wild-type mice. PLoS One 2011, 6:e18153.
198. Watanabe K., Kamiya D., Nishiyama A., Katayama T., Nozaki S., Kawasaki H., Watanabe Y., Mizuseki K., Sasai Y. Directed differentiation of telencephalic precursors from embryonic stem cells. Nat. Neurosci. 2005, 8:288-296.
199. Wei C.J., Li W., Chen J.F. Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies. Biochim. Biophys. Acta 2011, 1808:1358-1379.
200. Westmoreland J.J., Hancock C.R., Condie B.G. Neuronal development of embryonic stem cells: a model of GABAergic neuron differentiation. Biochem. Biophys. Res. Commun. 2001, 284:674-680.
201. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., Nie J., Jonsdottir G.A., Ruotti V., Stewart R., Slukvin I.I., Thomson J.A. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
202. Zeitlin S., Liu J.P., Chapman D.L., Papaioannou V.E., Efstratiadis A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat. Genet. 1995, 11:155-163.
203. Zermeno V., Espindola S., Mendoza E., Hernandez-Echeagaray E. Differential expression of neurotrophins in postnatal C57BL/6 mice striatum. Int. J. Biol. Sci. 2009, 5:118-127.
204. Zhang X.Z., Li X.J., Zhang H.Y. Valproic acid as a promising agent to combat Alzheimer's disease. Brain Res. Bull. 2010, 81:3-6.
205. Zhang N., An M.C., Montoro D., Ellerby L.M. Characterization of human Huntington's disease cell model from induced pluripotent stem cells. PLoS Curr. 2010, 2:RRN1193.
206. Zheng-Bradley X., Rung J., Parkinson H., Brazma A. Large scale comparison of global gene expression patterns in human and mouse. Genome Biol. 2010, 11:R124.
207. Zuccato C., Ciammola A., Rigamonti D., Leavitt B.R., Goffredo D., Conti L., MacDonald M.E., Friedlander R.M., Silani V., Hayden M.R., Timmusk T., Sipione S., Cattaneo E. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293:493-498.
208. Zuccato C., Liber D., Ramos C., Tarditi A., Rigamonti D., Tartari M., Valenza M., Cattaneo E. Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol. Res. 2005, 52:133-139.